Chemoimmunotherapy As Induction Treatment in Concurrent Chemoradiotherapy for Patients with Nasopharyngeal Carcinoma Stage IVa

Overview

Journal Ann Med

Publisher Informa Healthcare

Date 2025 Jan 21

PMID 39834281

Authors

Kun-Peng Wu

Qing-Qing Li

Xu-Qiang Luo

Xiao-Xi Wang

Yan-Zhen Lai

Dan Tian

Hong-Cheng Yang

Xue-Ling Wei

Lan-Ying Wang

Qiu-Ming Li

Dao Zhu

Si-Jie Chen

Yang-Si Li

Affiliations

Soon will be listed here.

Abstract

Background: Chemoimmunotherapy is the first-line therapy for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) and is currently the main induction treatment option for patients with locoregionally advanced NPC. However, it remains unclear whether combining immunotherapy with standard induction chemotherapy enhances its efficacy. This study aimed to evaluate the efficacy, toxicity, and survival outcomes of induction chemoimmunotherapy in patients with locoregionally advanced NPC.

Methods: This study analyzed 50 patients with stage IVa NPC between January 2020 and December 2023 in our hospital. Among them, 23 received induction chemoimmunotherapy, and 27 received induction chemotherapy. All patients underwent standard platinum-based concurrent intensity-modulated radiation therapy. We compared tumor response and toxicity during induction treatment and concurrent chemoradiotherapy (CCRT) between the two groups.

Results: The objective and complete response rates were significantly higher in the induction chemoimmunotherapy group compared to the induction chemotherapy group (95.7% vs 77.8%, and 39.1% vs 22.2%, respectively). All patients completed radical CCRT. Median follow-up was 24 months. Patients who received induction chemoimmunotherapy had longer event-free survival (EFS) compared to those who received induction chemotherapy ( = 0.029, Hazard Ratio and 95%confidence interval [CI]: 0.24 [0.07-0.85]). The 24-month EFS was higher in the induction chemoimmunotherapy group compared with the chemotherapy group (24-month EFS rates and 95%CI: 88.9% [95%CI: 68.3%-100%] vs 62.6% [95%CI: 43.1%-82.1%]). No significant differences in adverse events were observed between the two groups during induction treatment and CCRT.

Conclusions: Adding immunotherapy to induction chemotherapy may be an effective and safe choice for treating patients with stage IVa NPC.

References

Su Z, Siak P, Lwin Y, Cheah S . Epidemiology of nasopharyngeal carcinoma: current insights and future outlook. Cancer Metastasis Rev. 2024; 43(3):919-939. DOI: 10.1007/s10555-024-10176-9. View

Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J . Nasopharyngeal carcinoma. Lancet. 2019; 394(10192):64-80. DOI: 10.1016/S0140-6736(19)30956-0. View

Wu D, Li Y, Xu P, Fang Q, Cao F, Lin H . Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. Nat Commun. 2024; 15(1):2177. PMC: 10928200. DOI: 10.1038/s41467-024-46444-z. View

Liu L, Tang L, Chen Q, Zhang L, Guo S, Guo L . The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2015; 93(4):862-9. DOI: 10.1016/j.ijrobp.2015.08.003. View

Liang R . Precision drugs for recurrent or metastatic nasopharyngeal carcinoma (Review). Exp Ther Med. 2023; 26(6):585. PMC: 10665982. DOI: 10.3892/etm.2023.12284. View

Yao Y, Ouyang Q, Wang S, Li K, Luo Q, Qiu L . Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort. Oral Oncol. 2024; 154:106867. DOI: 10.1016/j.oraloncology.2024.106867. View

Mai H, Chen Q, Chen D, Hu C, Yang K, Wen J . Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021; 27(9):1536-1543. DOI: 10.1038/s41591-021-01444-0. View

Zheng B, Huang Z, Liu W, Zhao D, Xu X, Xiao S . A real-world evaluation of tislelizumab in patients with head and neck cancer. Transl Cancer Res. 2024; 13(2):808-818. PMC: 10928599. DOI: 10.21037/tcr-23-1502. View

Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N . Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer Cell. 2023; 41(6):1061-1072.e4. DOI: 10.1016/j.ccell.2023.04.014. View

10.

Li X, Fang Q, Du W, Zhang X, Dai L, Qiao Y . Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma. BMC Cancer. 2021; 21(1):622. PMC: 8157730. DOI: 10.1186/s12885-021-08373-8. View

11.

Jin Y, Qiang M, Wang Y, Lin Y, Jiang R, Cao W . The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis. Cancer Immunol Immunother. 2024; 73(7):125. PMC: 11088572. DOI: 10.1007/s00262-024-03698-2. View

12.

Yang Y, Qu S, Li J, Hu C, Xu M, Li W . Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021; 22(8):1162-1174. DOI: 10.1016/S1470-2045(21)00302-8. View

13.

Liu S, Li X, Yang J, Wen D, Guo S, Liu L . Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2024; 25(12):1563-1575. DOI: 10.1016/S1470-2045(24)00504-7. View

14.

Patel S, Gibson M, Deal A, Sheth S, Heiling H, Johnson S . A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma. Cancer. 2023; 129(21):3381-3389. DOI: 10.1002/cncr.34930. View

15.

Guven D, Stephen B, Sahin T, Cakir I, Aksoy S . Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis. Laryngoscope. 2023; 134(1):7-17. DOI: 10.1002/lary.30754. View

16.

Au K, Ngan R, Ng A, Poon D, Ng W, Yuen K . Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018; 77:16-21. DOI: 10.1016/j.oraloncology.2017.12.004. View

17.

Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R . Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024; 4(1):47-53. PMC: 11256708. DOI: 10.1016/j.jncc.2024.01.006. View

18.

Mai H, Chen Q, Chen D, Hu C, Yang K, Wen J . Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA. 2023; 330(20):1961-1970. PMC: 10685882. DOI: 10.1001/jama.2023.20181. View

19.

Lee N, Ferris R, Psyrri A, Haddad R, Tahara M, Bourhis J . Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021; 22(4):450-462. DOI: 10.1016/S1470-2045(20)30737-3. View

20.

Liu X, Zhang Y, Yang K, Zhang N, Jin F, Zou G . Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2024; 403(10445):2720-2731. DOI: 10.1016/S0140-6736(24)00594-4. View